ENTRY       D03259                      Drug
NAME        Gemtuzumab ozogamicin (USAN);
            Gemtuzumab ozogamicin (genetical recombination) (JAN);
            Gemtuzumab (INN);
            Mylotarg (TN)
PRODUCT     MYLOTARG (Wyeth Pharmaceuticals LLC)
CLASS       Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      Therapeutic category: 4239
            ATC code: L01FX02
            Product: D03259<JP/US>
EFFICACY    Antineoplastic, Anti-CD33 antibody
  DISEASE   Acute myeloid leukemia (CD33-positive) [DS:H00003]
  TYPE      Antibody-drug conjugate
TARGET      CD33 (SIGLEC3) [HSA:945] [KO:K06473]
  PATHWAY   hsa04640(945)  Hematopoietic cell lineage
METABOLISM  Enzyme: CYP3A4 [HSA:1576]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FX Other monoclonal antibodies and antibody drug conjugates
                 L01FX02 Gemtuzumab ozogamicin
                  D03259  Gemtuzumab ozogamicin (USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Gemtuzumab Ozogamicin
                D03259  Gemtuzumab ozogamicin (USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               423  Antibiotics
                4239  Others
                 D03259  Gemtuzumab ozogamicin (USAN); Gemtuzumab ozogamicin (genetical recombination) (JAN); Gemtuzumab (INN)
            Drug groups [BR:br08330]
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D03259  Gemtuzumab ozogamicin
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Cell adhesion molecules: Ig superfamiy
               SIGLEC family
                CD33 (SIGLEC3)
                 D03259  Gemtuzumab ozogamicin (USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D03259
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D03259
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D03259
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D03259
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D03259
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D03259
DBLINKS     CAS: 220578-59-6
            PubChem: 17397412
            NIKKAJI: J2.220.415G
///
